Skip to main content
Clinical and Molecular Hepatology logoLink to Clinical and Molecular Hepatology
. 2026 Aug 11;32(4):e2026.0402. doi: 10.3350/cmh.2026.0402

Long-term liver outcomes in Wilson’s disease: predictors of survival and hepatocellular carcinoma

Chien-Ting Hsu 1, Sung-Pin Fan 2, Jia-Feng Wu 3, Chin-Chang Huang 4,5, Tung-Hung Su 6,7, Tai-Chung Tseng 6, Ni-Chung Lee 3, Chin-Hsien Lin 2, Huey-Ling Chen 3,8,✉, Yen-Hsuan Ni 3,✉
PMCID: PMC13748839  PMID: 42576692

Abstract

Background/Aims

Wilson’s disease (WD) is an inherited and treatable disorder of copper metabolism with hepatic or neurological manifestations. It continues to pose challenges in clinical management, and long-term outcome data remain limited. This study investigated hepatic involvement and clinical outcomes in cohorts from Taiwan.

Methods

Longitudinal data from 146 patients with WD, retrieved from the medical database of a tertiary referral center, were analyzed (mean age at diagnosis 20.7±12.4 years; mean follow-up 16.8±10.8 years; maximum 51.8 years). All patients received standard treatment and care.

Results

Nine patients (6.2%) underwent liver transplantation, 6 patients (4.1%) died, and 3 patients (2.1%) developed hepatocellular carcinoma (HCC). Thrombocytopenia <100 K/μL at diagnosis was associated with reduced survival (P=0.0001). Univariate Cox regression identified thrombocytopenia at diagnosis as a strong predictor of liver transplantation or death (P=0.0001; hazard ratio 8.41; 95% confidence interval [CI] 2.97–23.78). Consistently, thrombocytopenia <100 K/μL was associated with reduced survival (P<0.0001) in an external cohort of 155 patients. In the original cohort, the estimated annual HCC risk was 0.12% (95% CI 0.03−0.36), increasing to 0.86% (95% CI 0.18−2.5) in those with thrombocytopenia at diagnosis (P=0.029). An exploratory Firth penalized logistic regression showed that older age at diagnosis was associated with higher odds of developing HCC (odds ratio 1.096; 95% CI 1.009–1.191; P=0.031).

Conclusions

WD patients have a high rate of liver fibrosis, regardless of whether they present with neurological and hepatic symptoms, and are at risk of developing HCC, warranting lifelong hepatic surveillance.

Keywords: Wilson’s disease, Hepatocellular carcinoma, Cirrhosis


Graphical Abstract

graphic file with name cmh-2026-0402f5.webp

INTRODUCTION

Wilson’s disease (WD) is a rare autosomal recessive disorder of copper metabolism, caused by pathogenic mutations in the ATP7B gene located on chromosome 13q14.3. It is characterized by abnormal accumulation of copper in the liver, brain, and other organs, leading to a wide spectrum of clinical manifestations [1,2], with a reported global prevalence between 1/10,000 and 1/30,000 [3]. It is an important disease in Taiwan with an average prevalence of 1.81 cases per 100,000 as estimated by the National Health Insurance Research Database [4].

WD with liver disease mainly occurs during childhood and adolescence, typically preceding neurologic manifestations by as many as ten years. Liver manifestations vary widely from asymptomatic cases with only biochemical abnormalities to overt cirrhosis and fulminant liver failure [5,6]. Approximately 60% of WD patients have hepatic and neurologic symptoms [7]; those with neurologic WD also have underlying hepatic involvement, which may be subtle and easily overlooked in clinical management [8]. Nevertheless, data on the prevalence of liver cirrhosis among patients presenting with neurological manifestations remain limited. The presence of cirrhosis at the time of diagnosis has been recognized as a prognostic factor for long-term outcomes in WD [9], and generally, a better prognosis is associated with an early diagnosis and good drug adherence [7,9-11]. The presence of cirrhosis at diagnosis is associated with a higher risk of mortality and the need for liver transplantation, yet evidence regarding its long-term complications remains limited.

Liver biopsy remains the reference standard for assessing the severity of necro-inflammatory activity, detecting steatosis and dry copper content in the hepatic tissue, a key feature of WD, and for staging fibrosis/cirrhosis [12]. For disease monitoring, non-invasive assessments have become the mainstay, employing measures such as the fibrosis-4 index (FIB-4), the aspartate aminotransferase-to-platelet ratio index (APRI), or transient elastography [12-15]. Given the limited evidence on long-term follow-up, particularly regarding hepatic prognosis in patients presenting with neurological manifestations, this study investigated liver involvement in WD and its impact on long-term outcomes.

MATERIALS AND METHODS

Patients and data collection

Clinical data were collected from the medical records of patients diagnosed with WD and followed at the National Taiwan University Hospital from January 2006 to June 2023. Of the 169 patients identified, 23 were excluded due to incomplete medical records regarding biochemical parameters, clinical outcomes, or treatment (Fig. 1). The remaining 146 patients diagnosed with WD at the National Taiwan University Hospital between 1964 and 2023 were included in the final analysis. Ethical approval was obtained from the Institutional Review Board of the National Taiwan University Hospital (Number 201911087RINA, 202010054RIND) and Chang Gung Memorial Hospital (CGMH 202500785A0).

Figure 1.

Figure 1.

Patient selection and clinical outcomes. A total of 169 patients diagnosed with WD were identified; 23 were excluded due to missing data. The remaining 146 patients were analyzed: 131 remained stable under therapy, 9 underwent liver transplantation, and 6 died. NTUH, National Taiwan University Hospital; WD, Wilson’s disease.

The diagnosis of WD relied on characteristic clinical features, biochemical findings, histological and/or genetic testing [5,16,17]. The ATP7B mutation was confirmed in 89 (60.9%) patients. The data collected included diagnostic age, symptoms period before diagnosis, Kayser-Fleischer ring, biochemical parameters, liver sonographic or computed tomography (CT) images, liver biopsy if available, and brain magnetic resonance imaging (MRI) images. Patients were classified according to their initial presentation as either hepatic or neurologic. Individuals with neurological or psychiatric manifestations at diagnosis were assigned to the neurologic form, whereas those without neuropsychiatric symptoms but presenting with abnormal liver function were categorized as hepatic form. Initial therapy was determined by the attending physicians in accordance with guideline recommendations [5,16,17], and treatment was switched to an alternative agent in cases of drug intolerance or insufficient clinical response. Patients for liver transplantation were selected by an interprofessional transplant team.

Poor medication adherence was defined retrospectively based on explicit medical-record documentation of irregular medication use, missed doses, self-discontinuation, or prolonged treatment interruption.

Validation cohort

A cohort of 155 patients diagnosed with WD between 1968 and 2025 at Chang Gung Memorial Hospital, Linkou, a tertiary referral center in Taiwan, was analyzed for external validation.

Fibrosis evaluation

Fibrosis was assessed at the time of diagnosis based on a liver biopsy or liver imaging (sonography, CT, or MRI). A total of 145 (99.3%) patients underwent liver sonography; 68 (46.6%) patients had a liver CT or MRI image, and 26 (17.8%) patients underwent a liver biopsy. Sonographic fibrosis was defined by typical ultrasonographic features, including coarse or heterogeneous hepatic echotexture, a nodular liver contour, hepatomegaly with caudate lobe hypertrophy, and signs of portal hypertension such as splenomegaly or ascites [18-20]. Decompensated cirrhosis was defined as biopsy-proven or liver images showing fibrosis or cirrhosis with any of the following: total bilirubin >2 mg/dL, international normalized ratio >2, or albumin <3.5 g/dL.

Follow-up and prognosis

Patients were followed in outpatient clinics at intervals of one to three months, hospitalized for evaluation of disease status, or managed for acute complications, liver failure, decompensated cirrhosis, or liver transplantation. Follow-up duration was defined as the interval between the first and the most recent hospital visit. FIB-4 index was employed as a non-invasive tool to evaluate liver fibrosis after treatment and was defined as: age in years × aspartate transaminase (AST) [U/L] / platelet (PLT) [109/L] × (alanine transaminase (ALT) [U/L] 1/2) [21,22]. Advanced fibrosis was defined as a FIB-4 value >3.25 [13,22]. APRI was additionally employed as a complementary age-independent fibrosis marker and was calculated as [(AST / upper limit of normal AST) × 100] / PLT count [109/L] [23]. Advanced fibrosis was defined as APRI >2 [24]. Overall survival was defined as the time from diagnosis to death from any cause or last followup, irrespective of liver transplantation. Native liver survival was defined as the survival time without liver transplantation.

Statistical analyses

The data were analyzed using MedCalc (ver. 20.1; Med-Calc Software, Ostend, Belgium) and STATA (ver. 17.0; StataCorp, College Station, TX, USA). Group comparisons were conducted using t-tests, chi-squared tests, Kaplan–Meier survival analysis with log-rank tests, multivariate Cox proportional hazards models, and receiver operating characteristic (ROC) curve analysis. A P-value <0.05 was considered statistically significant.

RESULTS

Clinical presentation

A total of 146 patients were analyzed (Table 1). The average age at diagnosis was 20.7±12.4 years (range: 3.0–57.5 years), and the mean age at the last follow-up was 37.5±15.6 years. The mean follow-up duration was 16.8±10.8 years (up to 51.8 years), corresponding to 2,458 patient-years of observation. Patients with hepatic form were diagnosed at a significantly younger age compared with those with neurologic form (P<0.0001; Table 1). The interval from symptom onset to diagnosis was shorter in the hepatic form than in the neurologic form, although the difference was not statistically significant (P=0.4560; Table 1). Among the 123 patients who underwent ophthalmologic assessment, Kayser-Fleischer rings were observed more frequently in the neurologic form compared with the hepatic form (P=0.0002; Table 1). Eighteen patients had decompensated cirrhosis at initial diagnosis, with more cases in the hepatic form group (21.5% vs. 1.5%; P=0.0006).

Table 1.

Baseline characteristics and outcomes of patients with Wilson’s disease

Variable Hepatic form (n=79) Neurologic form (n=67) P-value
Male sex 35 (44.3) 37 (55.2) 0.250
Age at diagnosis (yr) 15.8±10.7 26.5±11.8 <0.0001
Kayser-Fleischer ring 31 (47.0)* 46 (80.7)† 0.0002
Symptom to diagnosis (mo) 11.9±24.6§ 15.9±21.4‡ 0.456
Initial AST (IU/L) 108.3±115.8 31.2±14.6* <0.0001
Initial ALT (IU/L) 134.5±164.2 32.7±25.6* <0.0001
Initial PLT (K/μL) 214.6±119.2 173.8±71.4 0.016
Initial PLT <100 K/μL 16 (20.3) 9 (13.4) 0.430
Initial fibrosis or cirrhosis 35 (44.3) 48 (72.7)* 0.001
 Liver CT or MRI performed 39 (49.4) 29 (43.3) 0.570
 Sonography performed 79 (100) 66 (98.5) 0.930
 Liver biopsy performed 23 (29.1) 3 (4.5) 0.0003
Decompensated cirrhosis (INR>2, T-bil>2 mg/dL or Alb<3.5 g/dL) 17 (21.5) 1 (1.5) 0.0006
Follow-up time (yr) 16.1±9.8 17.7±12.0 0.369
Outcome
 Liver transplantation 6 (7.6) 3 (4.5) 0.663
 Death 3 (3.8) 3 (4.5) 0.832
 HCC 3 (3.8) 0 (0) 0.305
Latest PLT (K/μL) 212.5±101 207.4±84.4 0.744
Latest PLT <100 K/μL 16 (20.3) 8 (11.9) 0.276
Latest FIB-4 1.9±3.4 1.8±3.3 0.837
Latest FIB-4 >3.25 12 (15.6) 6 (9.1) 0.076
Latest APRI 1.3±5.2 0.7±2.1 0.348
Latest APRI >2 5 (6.3) 3 (4.5) 0.901
Genetic variants (n=89, including 55 hepatic form and 34 neurologic form)
 p.R778L, allelic number (allelic %) 34/110 (30.9) 15/68 (22.1) 0.269
 p.P992L, allelic number (allelic %) 15/110 (13.6) 9/68 (13.2) 0.881

Variables are expressed as mean±SD or n (%).

Alb, albumin; ALT, alanine transaminase; APRI, aspartate aminotransferase-to-platelet ratio index; AST, aspartate transaminase; CT, computed tomography; FIB-4, fibrosis-4 index; HCC, hepatocellular carcinoma; INR, international normalized ratio; MRI, magnetic resonance imaging; PLT, platelet; SD, standard deviation; T-bil, total bilirubin.

*

Data were available for 66 patients.

†

Data were available for 57 patients.

‡

Data were available for 31 patients.

§

Data were available for 48 patients.

Among the 79 patients with the hepatic form, all underwent sonographic evaluation, 39 (49.4%) received CT or MRI imaging, and 23 (29.1%) underwent liver biopsy. Of the 67 patients with the neurologic form, 66 (98.5%) had sonographic evaluation, 29 (43.3%) received CT or MRI imaging, and 3 (4.5%) underwent liver biopsy. Among patients who underwent liver biopsy, cirrhosis was histologically confirmed in 25 of 26 cases (96.2%). Among the 26 patients with both sonographic and liver biopsy data available, 25 had biopsy-confirmed cirrhosis or bridging fibrosis, of whom 12 also showed sonographic findings suggestive of cirrhosis or fibrosis. The only patient without cirrhosis on liver biopsy also had no sonographic evidence of cirrhosis or fibrosis. In addition, patients with sonographic findings suggestive of cirrhosis or fibrosis had significantly higher FIB-4 values than those without such findings (median 1.10 vs. 0.39, P<0.001). Overall, 83 of 145 patients (57.2%) fulfilled imaging or histologic criteria for liver fibrosis or cirrhosis, which was significantly more frequent among patients with the neurologic form (P=0.0011; Table 1).

Baseline laboratory findings at diagnosis

Mean ALT at diagnosis was significantly higher in patients with the hepatic form than in those with the neurologic form (P<0.0001; Table 1). Mean PLT counts were significantly lower in the neurologic form compared with the hepatic form (P=0.0167; Table 1). Thrombocytopenia (PLT<100 K/μL) was observed in 16 patients (20.3%) with the hepatic form and 9 patients (13.4%) with the neurologic form.

ATP7B gene mutation analysis was performed in most (60.9%) patients (Table 1), with at least one mutation identified, either homozygotes or compound heterozygotes, in all patients. The predominant pathogenic variant was p.R778L at exon 8 (allelic frequency of 27.5%), followed by p.P992L at exon 13 (13.5%).

Treatment

Most patients (71.2%) were initially treated with a chelating agent, zinc salts for 23 (15.8%) patients, and combination therapy (including chelating agent and zinc salts) for 19 (13.0%) patients. One patient who presented with acute liver failure (ALF) was treated with a combination therapy before liver transplantation. At the last follow-up, 9 (6.2%) patients required liver transplantation, with the other treatments including a chelating agent for 44 (32.1%) patients, zinc salts for 61 (44.5%) patients, and combination therapy for 32 (23.4%) patients (Fig. 2).

Figure 2.

Figure 2.

Treatment regimens at diagnosis and follow-up. At diagnosis, 71.2% of patients received chelating agents, 15.8% zinc salts, and 13.0% combination therapy. At the end of follow-up, among 137 non-transplant patients, 32.1% were on chelating agents, 44.5% on zinc salts, and 23.4% on combination therapy.

Long-term treatment information was available for most patients, with 45.5% of patients continuing on a lower dosage of chelating agent after the initial chelator, and 25.9% changed to full-dose zinc. Sixteen (11.2%) patients continued on zinc treatment after the initial first-line zinc treatment, and 25 (17.5%) patients experienced poor medication adherence to zinc and changed back to a chelator.

Outcomes

During the follow-up period, 9 patients (6.2%) underwent liver transplantation, 6 patients (4.1%) died, and 3 patients (2.1%) developed HCC. Time-dependent ROC analysis showed that the areas under the receiver operating characteristic curves (AUCs) of baseline PLT count for predicting liver transplantation or death were 0.79 (95% confidence interval [CI] 0.47–0.99), 0.78 (95% CI 0.53–0.95), and 0.86 (95% CI 0.69–0.97) at 10, 20, and 30 years, respectively. The corresponding optimal cutoffs were 83, 110, and 110 K/μL. For HCC, the time-dependent AUCs were 0.95, 0.94, and 1.00, with optimal cutoffs of 81, 82, and 85 K/μL, respectively. However, these estimates should be interpreted cautiously because only two HCC events had occurred by 30 years. Because the time-dependent cutoffs varied across follow-up periods, a PLT count <100 K/μL was selected as a readily applicable and clinically recognizable threshold for significant thrombocytopenia.

Seven patients underwent a liver transplantation for decompensated liver cirrhosis, one for ALF, and one for HCC. The liver transplantation was performed within the first year after diagnosis in 3 (33.3%) patients. Three patients with an initial neurologic presentation underwent a liver transplant due to decompensated liver cirrhosis at 2.6 years, 22 years, and 30.1 years after diagnosis. All patients who underwent liver transplantation had favorable outcomes, without major complications, and demonstrated normal liver function at the last follow-up.

The overall native liver survival rate was 96.6%, 95.1%, 91.2% and 77.6% at 1, 10, 20, and 30 years (Fig. 3A), respectively, with a significantly lower cumulative native liver survival rate after diagnosis in patients presenting with thrombocytopenia (PLT<100 K/μL) at diagnosis (log-rank: P<0.0001; Fig. 3B). The baseline clinical characteristics of patients with an initial PLT count <100 K/μL versus ≥100 K/μL are shown in Supplementary Table 1. Age at diagnosis, symptom-to-diagnosis interval, initial AST and ALT levels, and follow-up duration were comparable between the two groups.

Figure 3.

Figure 3.

Native liver and overall survival in WD. (A) Overall native liver survival after diagnosis. (B) Native liver survival was significantly lower in patients with an initial platelet (PLT) count <100 K/μL (log-rank P<0.0001). (C) Overall survival of all patients. (D) Patients with an initial PLT count <100 K/μL had significantly worse overall survival (log-rank P=0.0001). WD, Wilson’s disease.

During the follow-up period, six patients (4.1%) died, two due to non–disease-related event (one for pneumonia, one had no preceding event), three due to cirrhosis with hepatic failure, and one due to HCC. Overall survival was 98.6% at both 1 and 10 years, 95.7% at 20 years, and 88.2% at 30 years after WD diagnosis (Fig. 3C). The cumulative survival rate was significantly lower among patients with thrombocytopenia at diagnosis (PLT count below 100 K/μL; log-rank: P=0.0001; Fig. 3D).

To evaluate the potential impact of evolving diagnostic modalities and treatment practices over time, we performed a sensitivity analysis stratified by diagnostic era, using 2005 as the cutoff (diagnosis before 2005 vs. diagnosis after 2005). Kaplan–Meier analysis demonstrated no statistically significant differences in overall survival and native liver survival between the two groups (log-rank P=0.725 and P=0.5394, respectively) (Supplementary Fig. 1). We also evaluated the association between medication adherence and clinical outcomes. Kaplan–Meier analysis showed no statistically significant difference in native liver survival between the good adherence and poor adherence groups (log-rank P=0.1137).

Factors associated with outcomes

Patients with thrombocytopenia exhibited poorer overall and native liver survival (P=0.0001 and P<0.0001), with only 66.2% and 44.1% of patients with initial thrombocytopenia surviving 20 years and 30 years with their native liver.

Univariate and multivariable Cox proportional hazards analyses were performed to evaluate factors associated with liver transplantation or death (Supplementary Table 2). In the univariate analysis, thrombocytopenia at diagnosis (PLT <100 K/μL) was significantly associated with a higher risk of liver transplantation or death (hazard ratio [HR] 8.41; 95% CI 2.97–23.78; P=0.0001). This association remained significant in the multivariable model including age at diagnosis, clinical subgroup, and diagnostic era (HR 7.81; 95% CI 2.55–23.86; P=0.0003).

Kaplan-Meier analysis revealed that the cumulative advanced fibrosis (FIB-4 >3.25) at 10 and 20 years after the first diagnosis was 9.3% and 18.6% in patients with the hepatic form and 1.7% and 9.8% in the neurologic form (P=0.0843; Fig. 4A). The prevalence of advanced fibrosis was significantly higher in patients with thrombocytopenia at diagnosis compared with those without (P<0.0001; Fig. 4B). To address the age-related limitation of FIB-4, an additional analysis was performed using APRI as a complementary age-independent fibrosis marker. No significant difference in cumulative advanced fibrosis was observed between the hepatic and neurologic form groups when advanced fibrosis was defined as APRI >2 (log-rank P=0.4156; Fig. 4C). Patients with an initial PLT count <100 K/μL had a significantly higher cumulative incidence of advanced fibrosis defined by APRI than those with an initial PLT count ≥100 K/μL (log-rank P<0.0001; Fig. 4D). These findings suggest that the association between baseline thrombocytopenia and greater fibrosis burden was consistent across noninvasive fibrosis markers.

Figure 4.

Figure 4.

Cumulative advanced fibrosis in WD. (A) The cumulative advanced fibrosis, defined as FIB-4 >3.25, at 10 and 20 years after the first diagnosis was 9.3% and 18.6% in patients with the hepatic form and 1.7% and 9.8% in the neurologic form (log-rank P=0.0843). (B) Patients with initial platelet (PLT) count <100 K/μL had a significantly higher risk of advanced fibrosis, defined as FIB-4 >3.25, than those with PLT count ≥100 K/μL (log-rank P<0.0001). (C) No significant difference in the cumulative incidence of advanced fibrosis, defined as APRI >2, was observed between patients with the hepatic form and those with the neurologic form (log-rank P=0.4156). (D) Patients with an initial PLT count <100 K/μL had a significantly higher cumulative incidence of advanced fibrosis, defined as APRI >2, than those with an initial PLT count ≥100 K/μL (log-rank P<0.0001). APRI, aspartate aminotransferase-to-platelet ratio index; FIB-4, fibrosis-4 index; WD, Wilson’s disease.

Three patients (2.1%) with the hepatic form developed HCC at 45.6, 48.8, and 61.2 years of age; their corresponding ages at WD diagnosis were 44.6, 18.7, and 57.5 years, respectively. At diagnosis, their initial PLT counts were 44×10³/μL, 81×10³/μL and 90×10³/μL, respectively. One patient received a donor liver transplant with a whole liver graft 6 months after an HCC diagnosis, and another patient died without an adequate liver transplant donor. The third patient was lost to follow-up after the HCC diagnosis. Patients who developed HCC were significantly older at diagnosis (P=0.00054), had significantly lower initial PLT counts (P=0.033), and presented with thrombocytopenia (PLT<100 K/μL) at diagnosis (P=0.0047).

The estimated annual HCC risk for all patients was 0.12% (95% CI 0.03−0.36). Among WD patients presenting with initial thrombocytopenia (PLT <100 K/μL) at diagnosis, the annual risk of HCC was estimated at 0.86% (95% CI 0.18–2.5). This difference was statistically significant (P=0.029). Given the limited number of HCC events, an exploratory Firth penalized logistic regression analysis was performed. Older age at diagnosis was associated with higher odds of developing HCC, with a 9.6% increase in odds for each one-year increase in age (odds ratio 1.096; 95% CI 1.009–1.191; P=0.031).

External validation

In addition, we performed external validation using a cohort of 155 patients with WD from one other tertiary referral center. Baseline clinical characteristics are summarized in Supplementary Table 3. The mean age at diagnosis was 24.8±12.2 years, the mean follow-up duration was 5.7±5.8 years, and the maximum follow-up duration was 40.3 years. One patient (0.6%) developed HCC at 34 years of age, 10 years after diagnosis, and this patient had an initial PLT count of 81×10³/μL. Consistent with the findings in our original cohort, thrombocytopenia <100 K/μL at diagnosis was significantly associated with reduced overall survival and native liver survival (both log-rank P<0.0001) (Supplementary Fig. 2). Because only one patient developed HCC, age-dependent predictors of HCC could not be reliably evaluated in the external cohort.

DISCUSSION

Patients with WD generally have a favorable long-term outcome, especially when the diagnosis is made prior to the onset of cirrhosis or neurological involvement [7], and survival can be prolonged with chelation treatment and liver transplantation [5,9,25]. Most studies demonstrated outcomes as overall survival rates, depending on the severity of liver and neurological disease and drug compliance [5,7]. However, few studies evaluated the initial laboratory parameters with long-term follow-up outcomes, which is important for predicting outcomes and planning management strategies. The present study evaluated a dataset of long-term follow-up with liver outcomes, revealing liver fibrosis/cirrhosis in patients with WD, as well as a risk of HCC, regardless of whether their presenting symptoms were neurological or hepatic. In this study, we found that a PLT count below 100 K/μL predicted poor liver outcomes and reduced survival, and this association was externally validated in an independent cohort. PLT count is a readily available, widely accessible, and easily adaptable parameter that is convenient for clinicians to use. Our study highlights the importance of optimizing treatment and careful monitoring for this life-long disease.

Hepatobiliary malignancies, including HCC and intrahepatic cholangiocellular carcinomas, have been reported in WD [10,26], but there is limited data available for the rate of progression to HCC. Van Meer et al. [27] reported an estimated annual HCC risk of 0.09%, 0.14% in a subgroup of cirrhosis patients, but no increased risk of HCC in patients with cirrhosis. The present study showed an annual HCC risk of 0.12%, increasing to 0.86% in those with thrombocytopenia at diagnosis, and that patients who developed HCC were significantly older at diagnosis. An exploratory Firth penalized logistic regression analysis showed that older age at diagnosis was associated with increased odds of developing HCC. The 2022 practice guidance on WD from the American Association for the Study of Liver Diseases recommends that patients who have cirrhosis or regressed cirrhosis should undergo HCC screening and surveillance [8]. These data support the necessity of screening and surveillance for HCC in WD patients with cirrhosis, particularly in those diagnosed at an older age and those presenting with a low initial PLT count. To our knowledge, this is the first report to specify the risk group for the long-term follow-up of patients with WD.

WD is treatable, necessitating lifelong oral medication. The modalities for disease monitoring and cirrhosis/HCC surveillance should be carefully selected considering the benefit, risk, feasibility, and cost. Although liver biopsy is most useful during initial diagnosis and can predict outcomes, it is considered an optional diagnostic tool in some institutions and may not be suitable as a routine surveillance method during follow-up. Beinhardt et al. [9] reported that liver biopsies were performed in 165 out of 229 cases in Austria, with cirrhosis at diagnosis being the best predictor of death and the need for a liver transplant. In 182 pediatric patients included in the French Wilson’s disease national registry, only 36 (19.8%) had liver biopsies for diagnostic purposes [25]. Due to evolving diagnostic modalities over the past decades, particularly genetic testing, liver biopsy is no longer mandatory for a WD diagnosis. In the present study, only 26 (17.8%) patients had liver biopsy at initial diagnosis, so it is a less useful marker in predicting prognosis compared to thrombocytopenia. Sonographic fibrosis findings correlated with higher FIB-4 values and showed partial concordance with biopsy-confirmed advanced fibrosis in the subset with paired data; however, biopsy-based validation was limited by the small number of paired samples, and these findings should be interpreted with caution. PLT counts are widely accessible and typically performed in all patients during the initial assessment, so they should be recommended for the management of WD.

Furthermore, it is recommended that caution be exercised when classifying patients with the ‘hepatic’ or ‘neurological’ forms, as this may obscure the need for surveillance of other organ systems. The clinical expression is variable, with hepatic manifestations generally prevailing during childhood and adolescence, whereas the neurological manifestations typically emerge in the second and third decades [17,25,28], with approximately 60% of patients having both hepatic and neurological symptoms [7]. Beinhardt et al. [9] reported that 34% of patients predominantly presenting with neurologic symptoms at diagnosis had developed cirrhosis. Most patients with the neurologic form in our cohort had liver fibrosis at the initial evaluation, possibly due to the older age at diagnosis than in the hepatic form group. Moreover, 27.3% of the neurologic form patients had splenomegaly. The development of cirrhosis evolved slowly in WD patients, but is clinically important [5,7].

These findings provide a real-world perspective on how patients with WD receive treatment. For maintenance therapy, stable patients may continue a lower dosage of chelating agent or may be changed to zinc therapy after adequate initial chelator treatment [29]. In our cohort, around 45.5% patients continued a lower dosage of chelating agent after an initial chelator, whereas 25.9% of patients changed to full-dose zinc. Although zinc is associated with very few side effects, multiple daily doses are required, and long-term treatment adherence remains an issue [29], contributing to disease progression or death [5,7,30]. It has been reported that up to 44.8% clinically pre-symptomatic and 25.9% symptomatic WD patients have inadequate drug compliance [30,31]. Up to 13% of pediatric WD patients have poor drug compliance [25], but this may be underestimated based on limited studies. In our cohort, poor medication adherence, observed in 17.5% of patients who switched from zinc back to chelators, was not significantly associated with overall survival or native liver survival. However, the number of poor adherence group was relatively small, with limited events and potentially heterogenous factors, including varying degrees of nonadherences. Thus, these findings does not exclude a possible effect of poor adherence on long-term outcomes.

This study has several limitations. It is a retrospective study conducted in a single center. The external cohort reproduced the association between thrombocytopenia at diagnosis and adverse survival outcomes. However, it was not individually matched to the primary cohort for age at diagnosis or follow-up duration. In addition, only one patient developed HCC in the external cohort. Therefore, the association between older age at diagnosis and HCC identified in the primary cohort could not be independently validated. Secondly, only three patients developed HCC during the follow-up period, and the small number of events limited the statistical power of the multivariable analyses for HCC. An exploratory Firth penalized logistic regression analysis was therefore performed to reduce small-sample bias. Nevertheless, this approach cannot overcome the fundamental limitation imposed by the very small number of HCC events. These limitations restrict the generalizability of the study findings and highlight the need for further validation in larger multicenter cohorts with more HCC events before being used to establish a prediction model. The total number of liver transplantation or death events was limited. As a result, the multivariable Cox model may have been statistically underpowered and prone to overfitting, and the corresponding findings should be interpreted with caution. Thirdly, the rate of liver biopsy at initial diagnosis was relatively low, with only 17.8% undergoing the procedure, lacking the confirmation of fibrosis score. Comparisons among different diagnostic modalities were not possible. This study spanned several decades and included patients diagnosed with WD between 1964 and 2023, we have performed a sensitivity analysis stratified by diagnostic era (before vs. after 2005), and showed no significant differences between the two groups.

The FIB-4 >3.25 and APRI >2.0 cutoffs used in this study were originally derived and validated in viral hepatitis cohorts and have not been validated against liver histology in WD. In addition, the age weighting of FIB-4 may reduce its sensitivity in younger patients. Accordingly, these indices should be regarded as exploratory noninvasive surrogate markers rather than definitive measures of advanced fibrosis in this cohort. Liver biopsy or elastography may provide more accurate fibrosis staging, and future studies are needed. In addition, medication adherence was assessed retrospectively from medical records rather than using prospective standardized measures, which may have led to under ascertainment of nonadherence and misclassification bias.

In conclusion, fibrosis is common in all WD patients regardless of whether they present with hepatic or neurologic symptoms. Thrombocytopenia at diagnosis was also associated with poor survival and native liver survival. Importantly, WD patients are at risk of developing HCC, warranting lifelong hepatic surveillance.

Abbreviations

Alb

albumin

ALF

acute liver failure

ALT

alanine transaminase

APRI

aspartate aminotransferase-to-platelet ratio index

AST

aspartate transaminase

CT

computed tomography

FIB-4

fibrosis-4 index

HCC

hepatocellular carcinoma

HR

hazard ratio

INR

international normalized ratio

MRI

magnetic resonance imaging

PLT

platelet

ROC

receiver operating characteristic

SD

standard deviation

T-bil

total bilirubin

WD

Wilson’s disease

Study Highlights

• In 146 patients with Wilson’s disease followed for up to 51.8 years, 6.2% underwent liver transplantation, 4.1% died, and 2.1% developed HCC.

• Thrombocytopenia (<100 K/μL) at diagnosis was associated with poorer overall and native liver survival; this association was externally validated in a cohort of 155 patients.

• Wilson’s disease is associated with substantial liver fibrosis and a persistent risk of HCC, underscoring the need for lifelong hepatic surveillance.

Footnotes

Authors’ contribution

C.T.H.: acquisition of data, analysis and interpretation of data, statistical analysis, drafting of the manuscript, critical revision of the manuscript for important intellectual content. S.P.F.: acquisition of data, analysis and interpretation of data and assisted with manuscript. J.F.W., T.H.S. and T. C.T.: provided statistical methodological guidance and statistical analysis, critically reviewed the statistical content. C.C.H.: provided the external validation cohort and contributed to data interpretation. N.C.L.: acquisition of data, analysis and interpretation of data and assisted with manuscript revision. C.H.L.: study concept and design, and critical revision of the manuscript for important intellectual content. H.L.C. and Y.H.N.: study concept and design, critical revision of the manuscript for important intellectual content, and responsible for study supervision. All authors approved the final draft submitted.

Acknowledgements

The authors would like to thank all participants of this study; the staff of the Department of Medical Research, National Taiwan University Hospital Hsin-Chu Branch, for their assistance with statistical analysis; and the staff of the National Taiwan University Hospital–Integrative Medical Data Center (NTUH-iMD) for providing the clinical data. We also thank the National Taiwan University Hospital Medical Visualization Center (NTUH MedVis) for its contribution to the creation of the graphical abstract. This study was supported by National Taiwan University Hospital (115-SS0064, 111-UN0036, 110-A154, and 110-BIH019). The funder had no role in the study or manuscript preparation.

Conflicts of Interest

The authors have no conflicts to disclose.

SUPPLEMENTARY MATERIAL

Supplementary material is available at Clinical and Molecular Hepatology website (http://www.e-cmh.org).

Supplementary Figure 1.

Survival outcomes according to initial platelet count in the external validation cohort. (A) Overall survival and (B) Native liver survival stratified by initial platelet count. Thrombocytopenia <100 K/¥ìL at diagnosis was significantly associated with reduced overall survival and native liver survival.

Supplementary Figure 2.

Overall and native liver survival in WD stratified by diagnostic era. Among the 71 patients diagnosed before 2005, 10 experienced liver transplantation or death, whereas 5 of the 75 patients diagnosed after 2005 experienced this outcome. (A) Overall survival in patients diagnosed before and after 2005 showed no significant difference (log-rank P=0.725). (B) Native liver survival in patients diagnosed before and after 2005 showed no significant difference (log-rank P=0.5394). WD, Wilson’s disease.

Supplementary Table 1.

Baseline characteristics of patients with initial thrombocytopenia

Supplementary Table 2.

Univariate and multivariate Cox proportional hazards analysis of liver transplantation or death

Supplementary Table 3.

Baseline characteristics and outcomes of external validation cohort

REFERENCES

  • 1.Gitlin JD. Wilson disease. Gastroenterology. 2003;125:1868–1877. doi: 10.1053/j.gastro.2003.05.010. [DOI] [PubMed] [Google Scholar]
  • 2.Tao TY, Gitlin JD. Hepatic copper metabolism: insights from genetic disease. Hepatology. 2003;37:1241–1247. doi: 10.1053/jhep.2003.50281. [DOI] [PubMed] [Google Scholar]
  • 3.Lucena-Valera A, Perez-Palacios D, Muñoz-Hernandez R, Romero-Gómez M, Ampuero J. Wilson’s disease: revisiting an old friend. World J Hepatol. 2021;13:634–649. doi: 10.4254/wjh.v13.i6.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Tai CS, Wu JF, Chen HL, Hsu HY, Chang MH, Ni YH. Modality of treatment and potential outcome of Wilson disease in Taiwan: a population-based longitudinal study. J Formos Med Assoc. 2018;117:421–426. doi: 10.1016/j.jfma.2017.05.008. [DOI] [PubMed] [Google Scholar]
  • 5.European Association for Study of Liver EASL Clinical Practice Guidelines: Wilson’s disease. J Hepatol. 2012;56:671–685. doi: 10.1016/j.jhep.2011.11.007. [DOI] [PubMed] [Google Scholar]
  • 6.Kasztelan-Szczerbinska B, Cichoz-Lach H. Wilson’s disease: an update on the diagnostic workup and management. J Clin Med. 2021;10:5097. doi: 10.3390/jcm10215097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ott P, Ala A, Askari FK, Czlonkowska A, Hilgers RD, Poujois A, et al. Designing clinical trials in Wilson’s disease. Hepatology. 2021;74:3460–3471. doi: 10.1002/hep.32074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Schilsky ML, Roberts EA, Bronstein JM, Dhawan A, Hamilton JP, Rivard AM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2025;82:E41–E90. doi: 10.1002/hep.32801. [DOI] [PubMed] [Google Scholar]
  • 9.Beinhardt S, Leiss W, Stättermayer AF, Graziadei I, Zoller H, Stauber R, et al. Long-term outcomes of patients with Wilson disease in a large Austrian cohort. Clin Gastroenterol Hepatol. 2014;12:683–689. doi: 10.1016/j.cgh.2013.09.025. [DOI] [PubMed] [Google Scholar]
  • 10.Roberts EA, Schilsky ML. Current and emerging issues in Wilson’s disease. N Engl J Med. 2023;389:922–938. doi: 10.1056/NEJMra1903585. [DOI] [PubMed] [Google Scholar]
  • 11.Bruha R, Marecek Z, Pospisilova L, Nevsimalova S, Vitek L, Martasek P, et al. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int. 2011;31:83–91. doi: 10.1111/j.1478-3231.2010.02354.x. [DOI] [PubMed] [Google Scholar]
  • 12.Sini M, Sorbello O, Civolani A, Liggi M, Demelia L. Non-invasive assessment of hepatic fibrosis in a series of patients with Wilson’s disease. Dig Liver Dis. 2012;44:487–491. doi: 10.1016/j.dld.2011.12.010. [DOI] [PubMed] [Google Scholar]
  • 13.Paternostro R, Pfeiffenberger J, Ferenci P, Stättermayer AF, Stauber RE, Wrba F, et al. Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. Liver Int. 2020;40:894–904. doi: 10.1111/liv.14368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Hwang J, Yoon HM, Jung AY, Lee JS, Kim KM, Oh SH, et al. Diagnostic performance of ultrasound elastography and serologic fibrosis indices for evaluation of hepatic involvement in Wilson disease. J Ultrasound Med. 2020;39:2231–2242. doi: 10.1002/jum.15334. [DOI] [PubMed] [Google Scholar]
  • 15.Bierła JB, Jańczyk W, Konopka E, Wierzbicka-Rucińska A, Więckowski S, Obrycki Ł, et al. Fatty acid-binding protein 1 as a potential new serological marker of liver status in children with Wilson disease. J Pediatr Gastroenterol Nutr. 2021;73:455–462. doi: 10.1097/MPG.0000000000003128. [DOI] [PubMed] [Google Scholar]
  • 16.Roberts EA, Schilsky ML, American Association for Study of Liver Diseases (AASLD) Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089–2111. doi: 10.1002/hep.22261. [DOI] [PubMed] [Google Scholar]
  • 17.Socha P, Janczyk W, Dhawan A, Baumann U, D’Antiga L, Tanner S, et al. Wilson’s disease in children: a position paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:334–344. doi: 10.1097/MPG.0000000000001787. [DOI] [PubMed] [Google Scholar]
  • 18.Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology. 1989;172:389–392. doi: 10.1148/radiology.172.2.2526349. [DOI] [PubMed] [Google Scholar]
  • 19.Gaiani S, Gramantieri L, Venturoli N, Piscaglia F, Siringo S, D’Errico A, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol. 1997;27:979–985. doi: 10.1016/s0168-8278(97)80140-7. [DOI] [PubMed] [Google Scholar]
  • 20.Aubé C, Oberti F, Korali N, Namour MA, Loisel D, Tanguy JY, et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol. 1999;30:472–478. doi: 10.1016/s0168-8278(99)80107-x. [DOI] [PubMed] [Google Scholar]
  • 21.Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008;134:1670–1681. doi: 10.1053/j.gastro.2008.03.001. [DOI] [PubMed] [Google Scholar]
  • 22.Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325. doi: 10.1002/hep.21178. [DOI] [PubMed] [Google Scholar]
  • 23.Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526. doi: 10.1053/jhep.2003.50346. [DOI] [PubMed] [Google Scholar]
  • 24.Castera L, Rinella ME, Tsochatzis EA. Noninvasive assessment of liver fibrosis. N Engl J Med. 2025;393:1715–1729. doi: 10.1056/NEJMra2403308. [DOI] [PubMed] [Google Scholar]
  • 25.Couchonnal E, Lion-François L, Guillaud O, Habes D, Debray D, Lamireau T, et al. Pediatric Wilson’s disease: phenotypic, genetic characterization and outcome of 182 children in France. J Pediatr Gastroenterol Nutr. 2021;73:e80–e86. doi: 10.1097/MPG.0000000000003196. [DOI] [PubMed] [Google Scholar]
  • 26.Pfeiffenberger J, Mogler C, Gotthardt DN, Schulze-Bergkamen H, Litwin T, Reuner U, et al. Hepatobiliary malignancies in Wilson disease. Liver Int. 2015;35:1615–1622. doi: 10.1111/liv.12727. [DOI] [PubMed] [Google Scholar]
  • 27.van Meer S, de Man RA, van den Berg AP, Houwen RH, Linn FH, van Oijen MG, et al. No increased risk of hepatocellular carcinoma in cirrhosis due to Wilson disease during long-term follow-up. J Gastroenterol Hepatol. 2015;30:535–539. doi: 10.1111/jgh.12716. [DOI] [PubMed] [Google Scholar]
  • 28.Schilsky ML. Wilson disease: diagnosis, treatment, and follow-up. Clin Liver Dis. 2017;21:755–767. doi: 10.1016/j.cld.2017.06.011. [DOI] [PubMed] [Google Scholar]
  • 29.Schilsky ML, Roberts EA, Bronstein JM, Dhawan A, Hamilton JP, Rivard AM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2023;77:1428–1455. doi: 10.1002/hep.32805. [DOI] [PubMed] [Google Scholar]
  • 30.Masełbas W, Członkowska A, Litwin T, Niewada M. Persistence with treatment for Wilson disease: a retrospective study. BMC Neurol. 2019;19:278. doi: 10.1186/s12883-019-1502-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Dzieżyc K, Karliński M, Litwin T, Członkowska A. Compliant treatment with anti-copper agents prevents clinically overt Wilson’s disease in pre-symptomatic patients. Eur J Neurol. 2014;21:332–337. doi: 10.1111/ene.12320. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure 1.

Survival outcomes according to initial platelet count in the external validation cohort. (A) Overall survival and (B) Native liver survival stratified by initial platelet count. Thrombocytopenia <100 K/¥ìL at diagnosis was significantly associated with reduced overall survival and native liver survival.

Supplementary Figure 2.

Overall and native liver survival in WD stratified by diagnostic era. Among the 71 patients diagnosed before 2005, 10 experienced liver transplantation or death, whereas 5 of the 75 patients diagnosed after 2005 experienced this outcome. (A) Overall survival in patients diagnosed before and after 2005 showed no significant difference (log-rank P=0.725). (B) Native liver survival in patients diagnosed before and after 2005 showed no significant difference (log-rank P=0.5394). WD, Wilson’s disease.

Supplementary Table 1.

Baseline characteristics of patients with initial thrombocytopenia

Supplementary Table 2.

Univariate and multivariate Cox proportional hazards analysis of liver transplantation or death

Supplementary Table 3.

Baseline characteristics and outcomes of external validation cohort


Articles from Clinical and Molecular Hepatology are provided here courtesy of Korean Association for the Study of the Liver

RESOURCES